<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC514948/" ref="ordinalpos=2722&amp;ncbi_uid=483965&amp;link_uid=PMC514948" image-link="/pmc/articles/PMC514948/figure/f8/" class="imagepopup">Figure 8.  From: Anchoring of both PKA and 14-3-3 inhibits the Rho-GEF activity of the AKAP-Lbc <span class="highlight" style="background-color:">signaling</span> complex. </a></div><br /><div class="p4l_captionBody">Model for the 14-3-3-mediated inhibition of AKAP-Lbc. (<b>A</b>) AKAP-Lbc is activated in response to serum or LPA stimulation through a GÎ±12-mediated signaling pathway. (<b>B</b>) Elevation of the cellular concentration of cAMP activates the PKA holoenzyme anchored to AKAP-Lbc. The catalytic subunit released from the PKA holoenzyme can phosphorylate AKAP-Lbc on serine 1565. This induces the recruitment of 14-3-3, which inhibits the Rho-GEF activity of AKAP-Lbc.</div></div>